Track market-moving stories before they get noisy

BURLINGAME, Calif.--(BUSINESS WIRE)--Upstart Holdings, Inc. (NASDAQ: UPST), the leading artificial intelligence (AI) lending marketplace, today announced that the Office of the Comptroller of the Currency (OCC) has granted conditional approval for the company to establish Upstart Bank, N.A. The charter would allow Upstart to reduce operational, regulatory, and financial complexity for itself as well as for its third-party capital partners. The conditional approval follows Upstart's application,.

In the latest close session, Upstart Holdings, Inc. (UPST - Free Report) was down 2.15% at $28.64. This move lagged the S&P 500's daily loss of 0.14%. Meanwhile, the Dow lost 0.01%, and the Nasdaq, a tech-heavy index, lost 0.57%.

Shares of the company have depreciated by 6.96% over the course of the past month, underperforming the Finance sector's gain of 2.55%, and the S&P 500's gain of 0.25%.

The investment community will be paying close attention to the earnings performance of Upstart Holdings, Inc. in its upcoming release. The company is slated to reveal its earnings on August 4, 2026. It is anticipated that the company will report an EPS of $0.58, marking a 61.11% rise compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $354.89 million, up 37.93% from the year-ago period.

For the full year, the Zacks Consensus Estimates project earnings of $2.25 per share and a revenue of $1.43 billion, demonstrating changes of +29.31% and +36.53%, respectively, from the preceding year.

It is also important to note the recent changes to analyst estimates for Upstart Holdings, Inc. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the business and profitability.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.

The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. At present, Upstart Holdings, Inc. boasts a Zacks Rank of #3 (Hold).

In terms of valuation, Upstart Holdings, Inc. is presently being traded at a Forward P/E ratio of 12.99. This represents a premium compared to its industry average Forward P/E of 11.

It's also important to note that UPST currently trades at a PEG ratio of 0.32. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As of the close of trade yesterday, the Financial - Miscellaneous Services industry held an average PEG ratio of 0.96.

The Financial - Miscellaneous Services industry is part of the Finance sector. At present, this industry carries a Zacks Industry Rank of 186, placing it within the bottom 25% of over 250 industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.

Upstart's (UPST +1.67%) business has come a long way in recent years. The fintech stock was one of the biggest losers in the post-pandemic bear market as its profits evaporated in 2022, but since then, it has regrouped, returned to generally accepted accounting principles (GAAP) profitability, and delivered strong growth.

However, that hasn't been enough to please investors, at least so far this year, and concerns about its business model and the departure of CEO Dave Girouard have hung over the company, despite its continuing to deliver solid results.

As a result, the stock fell 19% in the first six months of 2026, according to data from S&P Global Market Intelligence. As you can see from the chart below, shares fell sharply through the first quarter before recouping some of those losses in Q2.

UPST data by YCharts

What happened with Upstart this year Upstart actually jumped out of the gate, scoring a buy rating from Truist early in the year, crediting its advantage over traditional credit scoring and its AI foundation. However, by the end of January, the stock was in the red.

Upstart tumbled in February as it gave investors two bitter pills to swallow. First, it said that co-founder Dave Girouard was stepping down as CEO, to be replaced by co-founder and then-CTO Paul Gu, and it reported fourth-quarter earnings, delivering solid results but offering underwhelming guidance.

Overall growth in the quarter was impressive, with loans originated up 86% to 455,788 and revenue up 35% to $296.1 million as the company targets smaller loans and lower-risk borrowers, which offer less of a premium and have led to lower take rates. That figure beat estimates at $288.6 million.

On the bottom line, adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) rose from $38.8 million to $63.7 million, and it reported a GAAP profit per share of $0.17.

However, the company guided 2026 adjusted EBITDA margin to fall slightly from 22% to 21%, and investors also seemed worried about declining take rates, suggesting its lending partners aren't paying as much as they previously were. The stock fell 15% on Feb. 11 on the news and continued to decline from there.

The stock began to come back in April, popping 13% on April 15 in response to comments from Morgan Stanley that downplayed the risks in the private credit market, which have weighed on Upstart.

Shares pulled back again following the first-quarter earnings report in May, as it delivered solid growth but similar concerns persisted, including its declining take rate. More importantly, its adjusted EBITDA margin fell from 20% to 13%, driven by higher sales and marketing expenses, and its net loss widened from $2.4 million to $6.6 million.

Image source: Getty Images.

What's next for Upstart The company maintained its guidance for the year in the Q1 report, and CEO Paul Gu bought 50,000 shares of the stock the following week in May, which is typically a bullish signal.

Management also offered guidance through 2028, calling for a compound annual growth rate of around 35% during 2025-2028 and an adjusted EBITDA margin of 28%. If it can execute on that, the stock should move higher, but this is still a risky stock, especially considering that interest rates are now expected to move higher by the end of the year.

On July 09, 2026, Upstart Holdings Inc (UPST) shares rose 4.5% today, currently priced at $33.23. This movement comes amid a 52-week range of $23.97 to $87.30,

Upstart Holdings, Inc. (UPST - Free Report) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.

Shares of this company have returned +6.4% over the past month versus the Zacks S&P 500 composite's +1.6% change. The Zacks Financial - Miscellaneous Services industry, to which Upstart belongs, has gained 1.4% over this period. Now the key question is: Where could the stock be headed in the near term?

While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.

Revisions to Earnings EstimatesRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.

Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.

Upstart is expected to post earnings of $0.55 per share for the current quarter, representing a year-over-year change of +52.8%. Over the last 30 days, the Zacks Consensus Estimate remained unchanged.

The consensus earnings estimate of $2.27 for the current fiscal year indicates a year-over-year change of +30.5%. This estimate has remained unchanged over the last 30 days.

For the next fiscal year, the consensus earnings estimate of $3.29 indicates a change of +44.9% from what Upstart is expected to report a year ago. Over the past month, the estimate has remained unchanged.

Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Upstart is rated Zacks Rank #3 (Hold).

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Revenue Growth ForecastEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

For Upstart, the consensus sales estimate for the current quarter of $354.89 million indicates a year-over-year change of +37.9%. For the current and next fiscal years, $1.43 billion and $1.86 billion estimates indicate +36.5% and +30.6% changes, respectively.

Last Reported Results and Surprise HistoryUpstart reported revenues of $308.21 million in the last reported quarter, representing a year-over-year change of +44.4%. EPS of $0.3 for the same period compares with $0.3 a year ago.

Compared to the Zacks Consensus Estimate of $289.36 million, the reported revenues represent a surprise of +6.51%. The EPS surprise was -23.08%.

Over the last four quarters, Upstart surpassed consensus EPS estimates two times. The company topped consensus revenue estimates three times over this period.

ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.

Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.

The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Upstart is graded D on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Upstart. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

-

BURLINGAME, Calif.--(BUSINESS WIRE)--Upstart Holdings, Inc. (NASDAQ: UPST), the leading artificial intelligence (AI) lending marketplace, will hold a conference call to discuss its second quarter 2026 financial results on Tuesday, August 4, 2026, at 1:30 p.m. PT / 4:30 p.m. ET. The company’s earnings press release and investor presentation will be available on its investor relations website at ir.upstart.com after the market closes that day.

Live webcast. The live webcast and a replay will be available on Upstart’s investor relations website.

Conference Call Dial-In. To access the live conference call in the United States and Canada: 800-330-6710, conference code 7744842. To access the live conference call outside of the United States and Canada: +1 312-471-1353, conference code 7744842.

About Upstart

Upstart (NASDAQ: UPST) is the leading AI lending marketplace, connecting millions of consumers to more than 100 banks and credit unions that leverage Upstart’s AI models and cloud applications to deliver superior credit products. With Upstart AI, lenders can approve more borrowers at lower rates while delivering the exceptional digital-first experience customers demand. More than 90% of loans are fully automated, with no human intervention by Upstart. Founded in 2012, Upstart’s platform includes personal loans, automotive loans, home equity lines of credit, and Upstart’s new Cash Line product, a revolving line of credit. Upstart is based in Burlingame, California.

More News From Upstart Holdings, Inc.

Back to Newsroom

HomeStock IdeasLong IdeasFinancials 

SummaryUpstart benefits from moderating macro risks, strong loan origination growth, and expanding funding partnerships, with the automated originations at 91% improving margins.The management reiterates strong FY2026/FY2028 guidance, with it underscoring a multi-year, profitable growth cadence despite the mixed FQ1'26 performance metrics.Readers are well advised to temper their expectations entering UPST's FQ2'26 earnings call, attributed to the likely lumpy loan originations during the prior Iran conflict.Otherwise, the stock remains compelling at a P/E of 14.95x and a 3Y PEG ratio of 0.40x against historical levels/peers, despite the recently outsized recovery from the March 2026 bottom.UPST remains a compelling Buy for the contrarian, despite the prolonged macroeconomic normalization, the high short interest at 28.03%, and the potentially lumpy FQ2'26 performance. Richard Drury/DigitalVision via Getty Images

I previously rated Upstart Holdings, Inc. (UPST) as a Buy in April 2026, thanks to the profitable growth prospects as observed in the FY2028 targets.

In this article, I shall discuss why UPST remains a

15.9K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

The analysis is provided exclusively for informational purposes and should not be considered professional investment advice. Before investing, please conduct personal in-depth research and utmost due diligence, as there are many risks associated with the trade, including capital loss.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Key Takeaways Upstart is entering a phase where loan growth, funding access and automation shape its next stage.AI drove 91% fully automated loans and supported about 3.5% more originations at equivalent risk.Auto and Home originations surged, but lower near-term take rates keep UPST's execution bar high. Upstart Holdings (UPST - Free Report) is entering a new phase in which loan growth, funding access and automation matter as much as headline revenues. The company still depends heavily on personal lending, but its platform is widening.

For investors, the question is whether larger lending categories can improve economics without adding balance sheet risk. That makes the next stage more about execution than simple market expansion.

How AI Is Expanding Across UpstartArtificial intelligence remains central to Upstart’s underwriting model, but the company is using it more broadly across operations. In first-quarter 2026, 91% of loans were fully automated with no human intervention by Upstart.

The technology is also being applied to servicing, collections, borrower conversations, payment features and quality assurance. Model accuracy improved by 1.4 points versus the benchmark, while expanded use of artificial intelligence to predict post-default recoveries supported about 3.5% more originations at equivalent risk.

Why Upstart Is Leaning Into Secured LendingUpstart is expanding beyond unsecured personal loans through Auto, Home and home equity line of credit products. Auto originations rose more than 300% year over year in first-quarter 2026, while Home originations increased about 250%.

These products open larger addressable markets and add servicing opportunities. More than one-fourth of Home loans were fully automated, and home equity line of credit time to close averaged six days from application to signing.

Why Capital-Light Models Matter for UPSTThe capital-light marketplace remains a key part of the UPST setup. In 2025, institutional investors purchased around 64% of loan principal, lending partners purchased 26% and Upstart held roughly 10% on its balance sheet.

Funding depth is central to scalability. The company has well more than half of funding supported by committed capital, added a 24-month forward-flow agreement in first-quarter 2026 and completed oversubscribed securitizations.

How Upstart’s Charter Could Change the SetupUpstart’s national bank charter application should be viewed as a regulatory and operational trend line rather than an immediate earnings event. The potential benefits include broader 50-state coverage, lower origination friction and faster technology and regulatory iteration.

The charter would not change the main funding strategy. Upstart still expects banks, credit unions and institutional investors to purchase the vast majority of platform loans, keeping the model focused on marketplace fees and servicing rather than balance sheet lending.

What Trend Investors Should Watch CloselyThe key tension is mix. Newer products and super-prime personal loans are scaling, but they carry lower near-term take rates. Contribution margin fell to 50% in first-quarter 2026 from 55% a year earlier and 53% in the prior quarter.

That does not erase the growth story, but it raises the bar for execution. Secured-product take rates may take 12 to 24 months or longer to mature, so investors need evidence that larger markets can produce better unit economics.

The Zacks Consensus Estimate for UPST’s sales suggests growth of 36.53% for 2026 and 30.61% for 2027.

Image Source: Zacks Investment Research

How UPST Scores Reflect This TransitionThe bottom line is that Upstart has meaningful exposure to trends shaping digital lending, but the investment case is still in transition. Affirm Holdings (AFRM - Free Report) brings a point-of-sale lending reference point to the same fintech credit debate.

SoFi Technologies (SOFI - Free Report) adds a broader consumer-finance platform comparison, especially for investors weighing scale, product breadth and funding structure. UPST currently carries a Zacks Rank #3 (Hold), which points to a more balanced near-term earnings-revision picture rather than a clear breakout signal. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The Style Scores are less supportive. UPST has a VGM Score of F, Value Score of D, Growth Score of F and Momentum Score of F. Since A and B scores are the most favorable, this weak style profile fits a stock with trend exposure but unsettled margin, valuation and momentum signals.

UPST weekly chart shows long-term trend reversal from bottom in process. Source: TradingView Technical Structure Favors the Bulls The subsequent formation of a symmetrical triangle consolidation pattern further strengthened the bullish technical outlook. All major moving averages were reclaimed, along with the downtrend line. Most recently, the pullback confirmed support near the downtrend line and the 20-day and 50-day moving averages. The two averages had converged near one another, reflecting price compression and the potential for an expansion in bullish momentum.

Support Holds the Key to Higher Targets Since the initial triangle breakout signal occurred on Monday above $34.02, traders will be watching for the first pullback and a subsequent resumption of the trend. Key support is near the breakout zone and a decline to that area would be normal. However, if support holds above that level, followed by renewed buying pressure, it will indicate stronger demand. Conversely, a failure to hold support and a move back into the triangle would signal weakness.

Initial upside targets begin with the 200-day moving average, currently near $38.92 and falling. Above that, a prior swing high at $41.64 from February marks the next resistance area, while the 78.6% Fibonacci retracement of the prior decline at $46.08 identifies the next upside target zone. Whether the breakout develops into a sustained advance will likely depend on how the stock behaves during its first meaningful pullback. Holding above the breakout zone would reinforce the bullish reversal signaled at the start of the week and increase the probability that a new intermediate-term uptrend is underway.

In the latest trading session, Upstart Holdings, Inc. (UPST - Free Report) closed at $33.66, marking a +2.09% move from the previous day. The stock's performance was ahead of the S&P 500's daily loss of 0.05%. Elsewhere, the Dow lost 0.09%, while the tech-heavy Nasdaq lost 0.24%.

Coming into today, shares of the company had gained 0.86% in the past month. In that same time, the Finance sector gained 2.3%, while the S&P 500 lost 1.42%.

Analysts and investors alike will be keeping a close eye on the performance of Upstart Holdings, Inc. in its upcoming earnings disclosure. On that day, Upstart Holdings, Inc. is projected to report earnings of $0.55 per share, which would represent year-over-year growth of 52.78%. Our most recent consensus estimate is calling for quarterly revenue of $354.89 million, up 37.93% from the year-ago period.

Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $2.27 per share and revenue of $1.43 billion, indicating changes of +30.46% and +36.53%, respectively, compared to the previous year.

Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Upstart Holdings, Inc. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.

The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Right now, Upstart Holdings, Inc. possesses a Zacks Rank of #3 (Hold).

From a valuation perspective, Upstart Holdings, Inc. is currently exchanging hands at a Forward P/E ratio of 14.55. For comparison, its industry has an average Forward P/E of 11.12, which means Upstart Holdings, Inc. is trading at a premium to the group.

We can also see that UPST currently has a PEG ratio of 0.35. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Financial - Miscellaneous Services industry had an average PEG ratio of 1.05 as trading concluded yesterday.

The Financial - Miscellaneous Services industry is part of the Finance sector. At present, this industry carries a Zacks Industry Rank of 103, placing it within the top 43% of over 250 industries.

The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.

Key Takeaways Upstart shares rose after a renewed Neuberger deal to invest up to $600M in platform-originated loans.Committed loan demand can help Upstart fund growth without relying heavily on its own balance sheet.Upstart's Q1 originations rose 61% to $3.4B, while revenues increased 44% to $308M. Shares of Upstart Holdings (UPST - Free Report) were up more than 3% yesterday as the fintech company added another funding win at a key time for its lending marketplace. The company announced a renewed forward-flow agreement with Neuberger Specialty Finance, under which Neuberger-managed funds are expected to invest in up to $600 million of consumer loans originated through Upstart’s platform.

This is encouraging as more committed loan demand can help Upstart fund growth without leaning heavily on its own balance sheet. That matters because Upstart’s model works best when banks, credit unions and institutional investors buy the loans while the company earns platform and servicing fees. A deeper funding base can also support more competitive borrower rates and a smoother customer experience.

This deal fits with Upstart’s broader push to expand both lending partners and capital partners. Earlier, Community Choice Credit Union and USF Credit Union selected Upstart for personal lending, giving qualified applicants access to credit union-branded digital loan offers through Upstart’s platform. These additions show that Upstart is finding demand among traditional financial institutions that want faster, AI-powered lending tools.

The company also has momentum in its latest results. In first-quarter 2026, originations rose 61% year over year to about $3.4 billion, while revenues increased 44% to $308 million. Upstart also reiterated its 2026 outlook for about $1.4 billion in revenue and $294 million in adjusted EBITDA. Its platform now connects consumers with more than 100 banks and credit unions, and more than 90% of loans are fully automated.

For investors, the Neuberger renewal is a positive signal for funding confidence, and recent credit union wins support platform growth. Still, Upstart remains sensitive to consumer credit conditions, capital market appetite and margin pressure. UPST looks better positioned than it did during tougher funding periods, but a Neutral view still makes sense until growth translates into steadier profits.

Over the past three months, shares of this Zacks Rank #3 (Hold) company have gained 25.1% compared with the industry's 8.6% growth.

Image Source: Zacks Investment Research

Stocks to ConsiderSome better-ranked stocks from the Zacks-Financial Miscellaneous Services sector are Alerus Financial, Inc. (ALRS - Free Report) and Chime Financial (CHYM - Free Report) . While Alerus Financial sports a Zacks Rank #1 (Strong Buy), Chime Financial carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for Alerus Financial’s 2026 earnings per share (EPS) is pegged at $2.95, indicating a 6.12% increase from the prior-year period.

The Zacks Consensus Estimate for CHYM’s 2026 EPS has been revised from 16 cents to 30 cents over the past two months.

Upstart Holdings, Inc. (UPST - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Shares of this company have returned +2.7% over the past month versus the Zacks S&P 500 composite's -1.3% change. The Zacks Financial - Miscellaneous Services industry, to which Upstart belongs, has lost 0.3% over this period. Now the key question is: Where could the stock be headed in the near term?

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Earnings Estimate RevisionsHere at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.

Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.

Upstart is expected to post earnings of $0.55 per share for the current quarter, representing a year-over-year change of +52.8%. Over the last 30 days, the Zacks Consensus Estimate remained unchanged.

The consensus earnings estimate of $2.27 for the current fiscal year indicates a year-over-year change of +30.5%. This estimate has remained unchanged over the last 30 days.

For the next fiscal year, the consensus earnings estimate of $3.29 indicates a change of +44.9% from what Upstart is expected to report a year ago. Over the past month, the estimate has changed +0.6%.

With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Upstart.

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Projected Revenue GrowthEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

In the case of Upstart, the consensus sales estimate of $354.89 million for the current quarter points to a year-over-year change of +37.9%. The $1.43 billion and $1.86 billion estimates for the current and next fiscal years indicate changes of +36.5% and +30.6%, respectively.

Last Reported Results and Surprise HistoryUpstart reported revenues of $308.21 million in the last reported quarter, representing a year-over-year change of +44.4%. EPS of $0.3 for the same period compares with $0.3 a year ago.

Compared to the Zacks Consensus Estimate of $289.36 million, the reported revenues represent a surprise of +6.51%. The EPS surprise was -23.08%.

Over the last four quarters, Upstart surpassed consensus EPS estimates two times. The company topped consensus revenue estimates three times over this period.

ValuationWithout considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.

While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.

As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Upstart is graded D on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Upstart. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

SummaryCompaniesCorgi has launched 88 ETFs since December, including a record 34 in a single dayA single photonics ETF accounts for nearly half of Corgi's $562 million assetsAnalysts said Corgi faces a battle for market share despite lower fees and backing from Y CombinatorPROVIDENCE, RHODE ISLAND, June 22 (Reuters) - It took more than a decade for BlackRock, the world's largest issuer of exchange-traded funds, to launch its first 300 products.

Corgi Investments, the venture-capital-based ​asset manager, plans to repeat that feat in less than a year, the company tells Reuters.

Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.

Corgi's explosion onto the scene and its ambitious goal reflect the U.S. exchange-traded fund market itself, ‌which has never been bigger or more crowded. In the first five months of 2026 alone, ETFs pulled in a record $837 billion in assets, according to ETFGI, an industry group, putting it on track to top $2 trillion in inflows this year. The number of funds is also exploding, with 148 launched in May alone.

Nearly a third of them came from Corgi.

"We're not super worried that this is a market with no room for new players," said Emily Yuan, co-founder of Corgi and chief operating officer of its ​parent company, the two-year-old AI-powered insurance company Corgi Insurance, which a financing round last month valued at $2.6 billion.

"Our thesis is that if you make good products that provide value, the money will come."

The money ​certainly has flowed into at least one of the 88 (and still counting) ETFs that Corgi has rolled out since it introduced its first product last December. The ⁠Corgi Lithography & Semiconductor Photonics ETF (EUV.Z), opens new tab, one of 34 funds it launched May 6 - at the time the largest ever one-day group launch - already has pulled in $273 million in assets, according to VettaFi. Corgi went on to launch ​35 more funds on June 2.

But the photonics fund is an anomaly. Corgi's runner-up, a leveraged ETF designed to deliver double the return of an index composed of founder-led companies launched in January, has attracted $20 million, while others ​hover around $3 million to $6 million, a more typical range for just-launched ETFs. The photonics ETF accounts for more than half of Corgi's $562 million in assets, VettaFi data shows.

Some market analysts say that Corgi may face an uphill battle in winning market share in a hyper-competitive market with few barriers to entry but a growing array of obstacles to success, in spite of high-profile backers like Silicon Valley startup accelerator Y Combinator. It provided startup financing to companies like Airbnb (ABNB.O), opens new tab, payment processor Stripe, and DoorDash (DASH.O), opens new tab and ​has anchored Corgi's financing rounds.

"Corgi is an unknown brand to financial advisors, who steer a lot of assets into ETFs, and trust doesn't happen overnight," said Nate Geraci, president of NovaDius Wealth Management and a veteran ETF ​analyst. Nor, Geraci added, does their current lineup of thematic, leveraged and buffer ETFs break new ground.

"Clearly, their goal is to flood the zone with lower-cost options and hope that competitive fee structure is compelling enough to allow a strategic ‌number to stick ⁠around," Geraci said.

For instance, the Corgi Magnificent 7 ETF (CMAG.Z), opens new tab, which offers exposure to mega-cap technology companies like Nvidia (NVDA.O), opens new tab and Tesla (TSLA.O), opens new tab, has a 0.2% fee, undercutting the 0.3% levied by Roundhill Investments' Roundhill Magnificent 7 (MAGS.Z), opens new tab.

"What we’re able to do is be a disruptor in this world, by building low-cost ETFs in house and finding a way to be profitable at a lower level of assets than a firm that has to pay a white-label provider to develop their products," said Edward Rumell, an ETF industry veteran who joined Corgi as its head of distribution at the beginning of this year.

When discussing the job with Corgi's founders, Rumell had already been startled by the pace at ​which Corgi was filing for the go-ahead to roll ​out new products and confesses he was unfamiliar ⁠with the "Y Combinator/Silicon Valley vibe" at Corgi. The firm boasts a 24-hour cafe on its premises - open to the public - and its assets include an actual Corgi dog, Trudy, for whose care employees are responsible.

"I'm the oldest member of the team, by at least 10 if not 20 years," acknowledges the 50-year-old Rumell.

But his nine-person team ​brings a new set of skills to developing, launching and marketing ETFs, Rumell adds, one that he said is increasingly important in the evolving investment environment.

"They're ​social media-savvy; they grew up trading ⁠on Robinhood (HOOD.O), opens new tab and understand how younger retail investors think about the market and using platforms like X and Reddit to reach them."

Whether or not that kind of young social-media-focused team gives Corgi an edge will be pivotal, said Todd Sohn, ETF analyst at Strategas.

"New players in the ETF ecosphere are coming either from the asset management industry, like MFS Investment Management, or are companies created by ETF industry veterans that focus on a particular niche," Sohn said. Corgi, he ⁠added, strikes him ​as "an anomaly."

"They are going to face a battle to position themselves and demonstrate that they have the connections they'll need to grow ​assets" or they will have to face closing down a large percentage of the dramatic number of new ETFs rather rapidly, Sohn said.

"They'll need to outhustle their rivals for this to work."

Yuan and Rumell said they plan to do just that.

"What we are doing is what ​we think is good for the market - to move fast, to disrupt business as usual," said Yuan. "So we might just as well do it."

Reporting by Suzanne McGee in Providence, Rhode Island; Editing by Colin Barr and Christopher Cushing

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Upstart Holdings, Inc. (UPST - Free Report) closed the most recent trading day at $31.32, moving -3.42% from the previous trading session. The stock's change was less than the S&P 500's daily loss of 0.37%. At the same time, the Dow added 0.29%, and the tech-heavy Nasdaq lost 1.33%.

The company's stock has climbed by 13.55% in the past month, exceeding the Finance sector's gain of 4.79% and the S&P 500's gain of 2.02%.

The investment community will be paying close attention to the earnings performance of Upstart Holdings, Inc. in its upcoming release. On that day, Upstart Holdings, Inc. is projected to report earnings of $0.55 per share, which would represent year-over-year growth of 52.78%. At the same time, our most recent consensus estimate is projecting a revenue of $354.89 million, reflecting a 37.93% rise from the equivalent quarter last year.

For the annual period, the Zacks Consensus Estimates anticipate earnings of $2.27 per share and a revenue of $1.43 billion, signifying shifts of +30.46% and +36.53%, respectively, from the last year.

Investors should also note any recent changes to analyst estimates for Upstart Holdings, Inc. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.

Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Upstart Holdings, Inc. is holding a Zacks Rank of #3 (Hold) right now.

Investors should also note Upstart Holdings, Inc.'s current valuation metrics, including its Forward P/E ratio of 14.31. This denotes a premium relative to the industry average Forward P/E of 10.89.

One should further note that UPST currently holds a PEG ratio of 0.35. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. By the end of yesterday's trading, the Financial - Miscellaneous Services industry had an average PEG ratio of 1.07.

The Financial - Miscellaneous Services industry is part of the Finance sector. At present, this industry carries a Zacks Industry Rank of 103, placing it within the top 43% of over 250 industries.

The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.

Issued on behalf of Conexeu Sciences Inc.

A clutch of new directors with Fortune 500 finance, M&A, and aesthetics pedigrees signals that the newly public tissue-regeneration company is building for commercialization — in one of medicine's most consequential frontiers.

, /PRNewswire/ -- American News Group News Commentary — There is a well-worn pattern in the life sciences: a company spends years on the science, goes public, and then — in the critical window right after listing — races to assemble the kind of leadership bench that can turn a promising platform into a real business. The names a young company recruits in that window say a great deal about its ambitions. On June 15, 2026, Conexeu Sciences Inc. (Nasdaq: CNXU), a preclinical-stage regenerative-tissue company that began trading only weeks earlier, offered a revealing answer: it expanded its board from six to nine directors, promoted a co-founder to Chief Commercial Officer, and added a prominent aesthetics-industry figure to its advisory board — five appointments in all, weighted heavily toward Fortune 500 finance, capital-markets, and commercialization experience.

The move is less about any single hire than about what the collective résumé signals. For a company whose lead technology is still preclinical, building a board stocked with big-company financial and operating discipline is a statement of intent: that Conexeu means to be judged not as a science project, but as a company on a path to commercialization in one of the most consequential frontiers in medicine — helping the body regenerate its own tissue. Whether it can deliver on that intent remains years from resolution, but the governance build-out is the kind of step investors in early-stage medtech tend to watch closely.

Key Takeaways

Board expanded from six to nine: Conexeu appointed Ana Bastiani-Posner, April Burke, and Andrew Costa as new directors, deepening its bench across healthcare finance, capital markets, M&A, and growth equity. A commercialization signal: Co-founder and director David Bogart was named Chief Commercial Officer to lead commercial strategy and operations, having helped shape the company's platform and regulatory pathway from inception. An aesthetics heavyweight on advisory: Melinda Farina, known as "The Beauty Broker" and founder of Integrated Aesthetics Consulting and Beauty Brokers Inc., joined the advisory board, reinforcing Conexeu's push into the aesthetics market. Pedigree that stands out: The new directors bring senior roles from Kyowa Kirin, Allergan, Novartis, Schering-Plough, Lucid Hearing, RX3 Growth Partners (the consumer growth-equity firm co-founded by NFL quarterback Aaron Rodgers), Morgan Stanley, and J.P. Morgan. Context — momentum and risk: The appointments follow Conexeu's May 2026 Nasdaq listing and June bell-ringing, as it advances its preclinical CXU™ platform toward a targeted early-2027 FDA 510(k) submission — a milestone, not a guarantee. Who Conexeu Just Brought In

The headline additions are notable for their financial and operating heft. Ana Bastiani-Posner, named chair of the Compensation Committee and a member of the Audit Committee, is a C-suite executive with more than two decades of leadership across Fortune 500 companies; she currently serves as Executive Vice President and Chief Financial Officer of Kyowa Kirin North America, where she helps oversee roughly $1.2 billion in annual revenue, and has held senior roles at Allergan, the New York Genome Center, Schering-Plough, and Novartis. April Burke, joining the Audit and Compensation Committees, is Executive Vice President and CFO of Lucid Hearing, with expertise spanning public companies, private-equity-backed organizations, capital allocation, M&A, and IPO readiness.

Andrew Costa, named chair of the Audit Committee, rounds out the new directors as an investor and growth-equity operator with fifteen years across private equity, investment banking, and military leadership. He is Co-Managing Partner of RX3 Growth Partners — the consumer-focused growth-equity firm co-founded by NFL quarterback Aaron Rodgers, investing in health, wellness, and active-lifestyle brands, where he sits on boards including Therabody — and previously held investment-banking roles at Morgan Stanley and J.P. Morgan, after serving as a Captain in the U.S. Air Force. Alongside the board additions, co-founder and director David Bogart was elevated to Chief Commercial Officer; a capital-markets and investor-relations strategist who has advised on more than $75 million in capital formation, Bogart has helped shape Conexeu's IP and regulatory strategy since inception. And on the advisory side, Melinda Farina — "The Beauty Broker," with nearly three decades in medical aesthetics — brings consumer-health, brand-development, and market-positioning expertise directly relevant to Conexeu's aesthetics ambitions.

"Conexeu is entering an exciting new phase of growth, and it is important that our leadership team reflects the breadth of expertise needed to support both our scientific vision and business strategy," said Miles Harrison, CEO and President of Conexeu Sciences, adding that he looked forward to working with Bogart to "build our commercial foundation, expand our pipeline, and position Conexeu for scalable growth."

What the Company Is Actually Building

The leadership news only matters because of what sits beneath it. Conexeu is a preclinical-stage regenerative-tissue company built around a proprietary bioregenerative extracellular matrix platform it calls CXU™. The extracellular matrix is the natural scaffolding that surrounds cells in the body, providing the structural and biochemical cues that tell cells where to go and how to rebuild. Conexeu's lead device candidate, Ten-Minute Tissue™, is a thermosensitive ECM engineered to remain fluid at room temperature and then transition into a stable gel scaffold in place, at body temperature, within roughly ten minutes — a property designed to let it conform to and fill the irregular, three-dimensional geometry of real wounds and soft-tissue defects that flat sheets and powders struggle to address.

The company frames its strategy with a deliberately simple refrain — "one formula, one device" — a single platform engineered to scale across multiple billion-dollar markets rather than the traditional one-molecule, one-indication model. Those target markets include advanced wound care, periodontal applications, and facial and body contouring (including the soft-tissue laxity associated with rapid GLP-1-driven weight loss), with longer-term expansion into 3D printing and biofabrication and even veterinary medicine. Conexeu has also unveiled a 3D-bioprinted regenerative breast matrix program, branded B.R.E.A.S.T.™, in preclinical development with the Wake Forest Institute for Regenerative Medicine, aimed at moving breast reconstruction beyond implants toward true tissue regeneration. The platform rests on more than a decade of university preclinical research and is protected by issued patents across the U.S., E.U., Japan, and Australia, with Conexeu holding full rights and no royalty obligations. Management is pursuing a predicate-based U.S. regulatory route, with a 510(k) submission for its initial wound-care indication targeted for early 2027.

A Sector With Powerful Tailwinds — and Heavyweight Players

Conexeu is wading into a field with genuine momentum. The shift from simply replacing or covering damaged tissue toward actively regenerating it spans several large, growing markets — advanced wound care, medical aesthetics and body contouring, and surgical reconstruction — all propelled by aging populations, the diabetes epidemic, and, increasingly, the GLP-1 weight-loss wave and the soft-tissue changes that follow it. To understand both the scale of the opportunity and the competition, it helps to look at the established public companies operating across the markets Conexeu is targeting. They are far larger, commercial, and more diversified, which makes them useful reference points rather than direct equivalents.

Smith+Nephew plc (NYSE: SNN) is one of the clearest reference points for the wound-care and tissue-repair side of Conexeu's platform. A global medical-technology company explicitly focused on the repair, regeneration, and replacement of soft and hard tissue, Smith+Nephew operates a leading advanced wound management business and bioinductive regenerative implants. It illustrates the scale and breadth a tissue-technology franchise can reach — and the entrenched, well-capitalized competition any newcomer in regenerative wound care must eventually reckon with.

AbbVie Inc. (NYSE: ABBV) anchors the aesthetics comparison through its Allergan Aesthetics division, the dominant force in medical aesthetics with a multibillion-dollar franchise spanning injectables and body contouring. AbbVie has been actively addressing the aesthetic consequences of GLP-1-driven weight loss — precisely the soft-tissue laxity Conexeu is targeting — making it a powerful illustration of how large the aesthetics opportunity is, and how formidable the incumbent is in the market Conexeu hopes to enter with a regenerative approach.

Establishment Labs Holdings Inc. (Nasdaq: ESTA) is perhaps the most thematically precise comparison for Conexeu's breast program. A pure-play breast-aesthetics-and-reconstruction company built around its Motiva implants and tissue-expander technologies, Establishment Labs has grown into a company with more than $200 million in annual revenue. As Conexeu advances its B.R.E.A.S.T.™ bioprinted matrix toward a regenerative alternative to implant-based reconstruction, Establishment Labs represents both the established approach Conexeu aims to leapfrog and the commercial scale a focused breast-health franchise can achieve.

Stryker Corporation (NYSE: SYK) rounds out the group as one of the largest and most respected medical-technology companies in the world, with a substantial presence in wound care, regenerative and reconstructive products, and surgical solutions. Stryker exemplifies the diversified, large-cap medtech model and the commercialization machinery — sales, regulatory, and distribution muscle — that turns medical innovation into durable revenue. It is the kind of established player whose scale a platform company like Conexeu would aspire to over the long term. These companies are referenced to illustrate the sector and do not imply any partnership, endorsement, affiliation, or comparable financial performance; they are vastly larger, commercial-stage, and more diversified than Conexeu, which is an early-stage, preclinical company.

The Risks Behind the Promise

It is essential to keep Conexeu's stage of development front and center. This is a preclinical-stage company; its CXU™ platform is an investigational device candidate whose safety and effectiveness have not been established and which has not been reviewed or cleared by the FDA. The company's own disclosures caution that preclinical findings from laboratory and animal models may not predict human results, that its planned early-2027 510(k) submission may slip or face additional FDA data requests, and that marketing clearance may be delayed, limited, or never granted. A strong board does not change the fundamental reality that the science must still be proven in the regulatory arena.

There are commercial and financial risks as well. As a newly public, development-stage company in a capital-intensive field, Conexeu will need continued access to financing to fund the long road from preclinical work through manufacturing, regulatory testing, and commercialization — a path most product candidates never complete. It faces enormous, well-funded competition from the very kinds of companies referenced above, and the predicate-based 510(k) route, while potentially faster, does not remove the inherent uncertainty of medical-device development. Investors should weigh the genuine credibility a strengthened board lends against the substantial execution risk that remains.

Why It Still Matters

For all those caveats, the logic behind Conexeu's leadership build-out is sound, and the trajectory of its field is unmistakable. Regenerative medicine is moving from a scientific aspiration toward a commercial reality, propelled by demographic and metabolic trends that are only intensifying — an aging world, a diabetes epidemic, a GLP-1 boom reshaping the aesthetics landscape, and a broad shift from replacing tissue toward rebuilding it. Bringing in directors and executives who have operated at the scale of Kyowa Kirin, Allergan, Novartis, and the major investment banks is precisely how an early-stage company signals it intends to compete in that future rather than merely research it.

Whether Conexeu converts that intent into cleared products and durable revenue will be decided over years, in manufacturing suites and regulatory reviews, not in board announcements. But the company is assembling the pieces — a differentiated platform, a multi-market strategy, and now a leadership team built for commercialization — to pursue one of the most compelling questions in modern medicine: not how to replace what the body has lost, but how to help it rebuild. For investors tracking where regenerative medicine is headed, Conexeu's post-listing moves are a small but telling marker of a company positioning itself for the long game.

CONTINUED … Learn more about Conexeu Sciences Inc. at: https://www.conexeu.com

SEE WHAT THE MARKET IS TALKING ABOUT BEFORE IT MOVES

Eagle Eye reads social, forum, and news chatter across thousands of investor conversations in real time — and surfaces the tickers the crowd is piling into, along with the sentiment and catalysts behind them.

Explore Eagle Eye free (for now) at https://Eagle-Eye.dev

CONTACT:

American News Group

[email protected]

SOURCES:

[1] Conexeu Sciences Inc. — "Conexeu Expands Board, Executive, and Advisory Leadership With Five Appointments Post Nasdaq Listing" (June 15, 2026; primary source for the board expansion, appointee bios, committee assignments, CXU™/Ten-Minute Tissue™ platform, and CEO Miles Harrison quote):

https://www.conexeu.com/resources/conexeu-expands-board-executive-and-advisory-leadership-with-five-appointments-post-nasdaq-listing

[2] Conexeu Sciences Inc. — "Conexeu Sciences Commences Trading on Nasdaq Under Ticker Symbol 'CNXU'" (May 21, 2026; Nasdaq listing, platform overview):

https://www.conexeu.com/resources/conexeu-sciences-commences-trading-on-nasdaq-under-ticker-symbol-cnxu

[3] Conexeu Sciences Inc. — "Conexeu Sciences Reports Manufacturing Scale Up and Regulatory Progress for Lead CXU™ Wound Care Program" (June 8, 2026; Q1 2027 510(k) plan, CDMO transfer, Ten-Minute Tissue™):

https://www.conexeu.com/resources/conexeu-sciences-reports-manufacturing-scale-up-and-regulatory-progress-for-lead-cxu-tm-wound-care-program

[4] Conexeu Sciences Inc. — "Conexeu Sciences Initiates Preclinical Development Program for B.R.E.A.S.T.™ Bioregenerative Matrix Platform with Wake Forest Institute for Regenerative Medicine" (May 27, 2026):

https://www.conexeu.com/resources/conexeu-sciences-initiates-preclinical-development-program-for-b-r-e-a-s-t-tm-bioregenerative-matrix-platform-with-wake-forest-institute-for-regenerative-medicine

[5] Establishment Labs Holdings Inc. — FY2025 results and company profile (NASDAQ: ESTA; breast aesthetics & reconstruction, Motiva, ~$211M 2025 revenue; sector/peer context with SNN, ABBV, SYK):

https://stockanalysis.com/stocks/esta/

DISCLAIMER:

Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a digital media distribution and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances.

American News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). This article is being distributed by American News Group on behalf of MIQ. MIQ has been paid a fee for Conexeu Sciences Inc. advertising and digital media from Creative Direct Marketing Group ("CDMG"). This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this article or email as the basis for any investment decision. MIQ does not own shares of Conexeu Sciences Inc. but reserves the right to buy and sell shares of Conexeu Sciences Inc. at any time without any further notice. There may be 3rd parties who may have shares of Conexeu Sciences Inc., and may liquidate their shares which could have a negative effect on the price of the stock. We also expect further compensation as an ongoing digital media effort to increase visibility for the company; no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been reviewed and approved on behalf of Conexeu Sciences Inc. by CDMG; this is a digital media distribution.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our publication is not trustworthy unless verified by their own independent research. Comparisons to other companies referenced in this publication are for contextual and illustrative purposes only and do not imply any partnership, endorsement, affiliation, or comparable financial performance. Forward-looking statements regarding leadership, preclinical and clinical development, manufacturing, regulatory submissions and clearances (including the planned first-quarter 2027 510(k) submission), reimbursement, market size, and commercialization are subject to risks and uncertainties, and actual results may differ materially. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

In the latest close session, Upstart Holdings, Inc. (UPST - Free Report) was down 4.06% at $30.50. The stock's change was less than the S&P 500's daily gain of 0.5%. Elsewhere, the Dow saw an upswing of 0.7%, while the tech-heavy Nasdaq appreciated by 0.31%.

The company's shares have seen an increase of 7% over the last month, surpassing the Finance sector's gain of 1.89% and the S&P 500's loss of 0.23%.

The upcoming earnings release of Upstart Holdings, Inc. will be of great interest to investors. The company is forecasted to report an EPS of $0.55, showcasing a 52.78% upward movement from the corresponding quarter of the prior year. Our most recent consensus estimate is calling for quarterly revenue of $354.89 million, up 37.93% from the year-ago period.

For the full year, the Zacks Consensus Estimates are projecting earnings of $2.27 per share and revenue of $1.43 billion, which would represent changes of +30.46% and +36.53%, respectively, from the prior year.

Any recent changes to analyst estimates for Upstart Holdings, Inc. should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the business and profitability.

Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Upstart Holdings, Inc. presently features a Zacks Rank of #3 (Hold).

Looking at its valuation, Upstart Holdings, Inc. is holding a Forward P/E ratio of 14.02. Its industry sports an average Forward P/E of 10.68, so one might conclude that Upstart Holdings, Inc. is trading at a premium comparatively.

Meanwhile, UPST's PEG ratio is currently 0.34. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. UPST's industry had an average PEG ratio of 0.99 as of yesterday's close.

The Financial - Miscellaneous Services industry is part of the Finance sector. This industry, currently bearing a Zacks Industry Rank of 143, finds itself in the bottom 42% echelons of all 250+ industries.

The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.

NEW YORK, June 05, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Upstart Holdings, Inc. (NASDAQ: UPST) between May 14, 2025 and November 4, 2025, inclusive (the “Class Period”), of the important June 8, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Upstart securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Upstart class action, go to https://rosenlegal.com/submit-form/?case_id=58653 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 8, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Model 22 frequently overreacted to negative macroeconomic signals in performing its risk-separation processes; (2) accordingly, Model 22’s overall accuracy and propensity to increase loan approval rates was overstated; (3) Model 22’s overly conservative assessment of credit and macroeconomic conditions was having a significant negative impact on Upstart’s revenue results, rendering Upstart’s previously issued full year 2025 revenue guidance unreliable and/or unrealistic; and (4) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Upstart class action, go to https://rosenlegal.com/submit-form/?case_id=58653 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

New York, New York--(Newsfile Corp. - June 6, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Upstart Holdings, Inc. (NASDAQ: UPST) between May 14, 2025 and November 4, 2025, inclusive (the "Class Period"), of the important June 8, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Upstart securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Upstart class action, go to https://rosenlegal.com/submit-form/?case_id=58653 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 8, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Model 22 frequently overreacted to negative macroeconomic signals in performing its risk-separation processes; (2) accordingly, Model 22's overall accuracy and propensity to increase loan approval rates was overstated; (3) Model 22's overly conservative assessment of credit and macroeconomic conditions was having a significant negative impact on Upstart's revenue results, rendering Upstart's previously issued full year 2025 revenue guidance unreliable and/or unrealistic; and (4) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Upstart class action, go to https://rosenlegal.com/submit-form/?case_id=58653 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/300338

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

, /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Upstart Holdings, Inc. (NASDAQ: UPST) between May 14, 2025 and November 4, 2025, inclusive (the "Class Period"), of the important June 8, 2026.

So what: If you purchased Upstart securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Upstart class action, go to https://rosenlegal.com/submit-form/?case_id=58653 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 8, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Model 22 frequently overreacted to negative macroeconomic signals in performing its risk-separation processes; (2) accordingly, Model 22's overall accuracy and propensity to increase loan approval rates was overstated; (3) Model 22's overly conservative assessment of credit and macroeconomic conditions was having a significant negative impact on Upstart's revenue results, rendering Upstart's previously issued full year 2025 revenue guidance unreliable and/or unrealistic; and (4) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. 

To join the Upstart class action, go to https://rosenlegal.com/submit-form/?case_id=58653 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

     Laurence Rosen, Esq.
     Phillip Kim, Esq.
     The Rosen Law Firm, P.A.
     275 Madison Avenue, 40th Floor
     New York, NY 10016
     Tel: (212) 686-1060
     Toll Free: (866) 767-3653
     Fax: (212) 202-3827
     [email protected]
     www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

, /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Upstart Holdings, Inc. ("Upstart" or "the Company") (NASDAQ: UPST) for for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of UPST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD: May 14, 2025 to November 4, 2025

DEADLINE: June 8, 2026

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Upstart overstated the accuracy of its "Model 22" AI. The AI's poor decision making impacted the Company's financial results. Based on these facts, Upstart's public statements were false and materially misleading throughout the class period.

If you are a shareholder who suffered a loss, contact us to participate.

WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.

Join the case to recover your losses.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]

SOURCE DJS Law Group LLP

LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Upstart Holdings, Inc. (“Upstart” or “the Company”) (NASDAQ: UPST) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s securities between May 14, 2025 and November 4, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before June 8, 2026.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Upstart’s “Model 22” AI frequently reacted poorly to macroeconomic signals. The Company overstated Model 22’s overall accuracy. The Company’s AI models were having a negative impact on its business performance. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Upstart, investors suffered damages.

Join the case to recover your losses

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Upstart Holdings, Inc. (“Upstart” or the “Company”) (NASDAQ: UPST) and reminds investors of the June 8, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608322251/en/

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Model 22 frequently overreacted to negative macroeconomic signals in performing its risk-separation processes; (2) accordingly, Model 22’s overall accuracy and propensity to increase loan approval rates was overstated; (3) Model 22’s overly conservative assessment of credit and macroeconomic conditions was having a significant negative impact on Upstart’s revenue results, rendering the Company’s previously issued FY 2025 revenue guidance unreliable and/or unrealistic; and (4) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

The truth began to emerge on November 4, 2025, when Upstart issued a press release reporting its financial results for the third quarter (“Q3”) of 2025. Upstart reported, inter alia, Q3 2025 revenue of $277 million, missing its previously issued Q3 2025 revenue guidance of approximately $280 million, as well as consensus estimates by $2.62 million. Upstart also reported that it expected to generate revenue of only $288 million in the fourth quarter (“Q4”) of 2025, significantly below consensus estimates of $303.7 million. Further, Upstart negatively revised its FY 2025 revenue guidance to approximately $1.035 billion, versus the $1.06 billion consensus estimate and its prior guidance of approximately $1.055 billion, as well as its expected FY 2025 revenue from fees, which it reduced to approximately $946 million from its prior outlook of approximately $990 million.

The same day, during a related earnings call, Defendants blamed Upstart’s disappointing results on Model 22, which they revealed had “overreact[ed]” to macroeconomic signals in the quarter, reducing borrower approvals and conversion rates. Defendants also acknowledged that they had “knowingly” calibrated their AI model to be “more conservative on the credit side in earlier parts of the quarter”, and that the negative impacts of Model 22’s “overresponsive[ness]” to macroeconomic signals in the quarter would continue to negatively impact revenues in Q4 2025, resulting in Upstart’s negatively revised FY 2025 financial guidance.

Following these disclosures, Upstart’s stock price fell $4.49 per share, or 9.71%, to close at $41.75 per share on November 5, 2025.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Upstart’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Upstart class action, go to www.faruqilaw.com/UPST or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260608322251/en/

NEW YORK, June 08, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Upstart Holdings, Inc. (NASDAQ: UPST) between May 14, 2025 and November 4, 2025, inclusive (the “Class Period”), of the important June 8, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Upstart securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Upstart class action, go to https://rosenlegal.com/submit-form/?case_id=58653 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 8, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Model 22 frequently overreacted to negative macroeconomic signals in performing its risk-separation processes; (2) accordingly, Model 22’s overall accuracy and propensity to increase loan approval rates was overstated; (3) Model 22’s overly conservative assessment of credit and macroeconomic conditions was having a significant negative impact on Upstart’s revenue results, rendering Upstart’s previously issued full year 2025 revenue guidance unreliable and/or unrealistic; and (4) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Upstart class action, go to https://rosenlegal.com/submit-form/?case_id=58653 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

watch now

In the increasingly competitive AI chip market, there's another startup in production that claims an advantage over Nvidia, the world's most valuable company.

D-Matrix, located three miles away from Nvidia's Silicon Valley headquarters, says its chips can run inference workloads 10 times faster and using five times less energy than a standalone graphics processing unit from the market leader — as long as the workloads are small.

The new inference chip, called Corsair, takes a novel approach to memory that's similar to Cerebras and Groq. With tech giants demanding all the computing resources they can get their hands on, it's becoming clear that there's substantial opportunity for smaller players to find their niche.

Cerebras, founded in 2015, held a blockbuster IPO last month, raising over $5.5 billion, and is now valued at over $50 billion. And Groq's assets were bought by Nvidia for $20 billion in December, making it the AI giant's largest purchase to date. Nvidia then released a new Groq chip at GTC in March, called a language processing unit.

"This is a $1 trillion market in the making," D-Matrix co-founder and CEO Sid Sheth told CNBC in an interview, adding that he has no intention of selling the company. "Can the market support yet another public company? Absolutely."

Founded in 2019, D-Matrix has raised around $500 million so far, putting it at around a $2 billion valuation. Microsoft was one of the investors, through its M12 venture arm. That's notable because of Microsoft's own chip ambitions, including its Maia 200 chip for AI inference, new PC processors built with Nvidia, and an in-house quantum computing chip announced last week.

Sheth won't name Corsair customers yet, but said he has commitments from high-profile hyperscalers, neoclouds and frontier AI labs eager to get their hands on as much compute as possible. D-Matrix begins shipping to those customers this month. About 90% of them are in the U.S., while overseas customers are in the Middle East and Southeast Asia, Sheth said.

"Quite often they sell to customers to use this stuff in conjunction with Nvidia," said semiconductor analyst Stacy Rasgon of Bernstein Research, adding that the different chips are better at different tasks. "Sounds like he's got a fair number of actual, real customer engagements."

D-Matrix's Corsair chip achieves low latency inference on low power by tightly integrating memory and compute on a single chip.

Like Groq and Cerebras, D-Matrix relies on SRAM, a type of memory that can be made at logic fabs like Taiwan Semiconductor Manufacturing Company and integrated on the same chip. GPUs rely on large amounts of another kind of memory called DRAM that's packaged into stacks of high bandwidth memory added around the logic chip.

That DRAM is also what's in short supply from Micron, Samsung and SK Hynix.

"We're not running into a chokepoint around DRAM with our product because our product doesn't really rely on DRAM to be successful," Sheth said.

The big downside to D-Matrix's approach is that SRAM can't handle massive reasoning models, according to Rick Bahr, adjunct professor of electrical engineering at Stanford University.

While on-chip SRAM enables "remarkable inference speeds" because data has to travel such short distances, it can't handle the trillions of parameters that now make up large models from leaders like OpenAI and Anthropic.

"That number of parameters just simply can't be be put onto an SRAM-based design," Bahr said. "That's the big challenge."

Sheth says Corsair is designed for AI inference, where "you're optimizing for interactivity or speed" over language size. Think chatbots, voice agents and agentic tools like Claude Code and OpenClaw.

When paired with an Nvidia Blackwell GPU, D-Matrix says, citing research from Gimlet Labs, that Corsair can run inference 10 times faster, three times cheaper and up to five times more energy efficiently than a standalone GPU.

Read more CNBC tech newsBezos opens up about AI startup Prometheus after $12 billion raise: 'We're not being secretive'DoorDash lets customers use photos, prompts to order food and book reservations in latest AI pushAs OpenAI leans into enterprise business, Apple and Google set sights on the massesPalantir's Karp says businesses are 'unhappy' with the frontier AI labsNvidia CEO Jensen Huang said last week that his company remains the leader in low-cost inference with its leading Vera Rubin system because it's not just about speed.

At Computex in Taiwan, Huang said "the reason for that is we integrate everything, we design everything from the ground up, we simulate the entire system and we use extreme co-design."

D-Matrix sells four Corsair chips packaged together inside a card that slides into slots in a data center server rack and costs tens of thousands of dollars, Sheth said.

It's a plug-and-play approach that differentiates D-Matrix from Cerebras and Groq, according to Sheth, who called Corsair the "densest SRAM solution in the market today," with up to 128 gigabytes of SRAM memory in a single server rack.

D-Matrix also teamed up with Arista, Broadcom and Super Micro to build a full rack-scale system called SquadRack for deploying its chips in AI data centers.

The chip is made in Taiwan on TSMC's 6-nanometer node. D-Matrix's next chip, Raptor, is scheduled to launch next year on TSMC 4 nanometer, which Sheth said could run out of the Taiwanese company's factory in Arizona.

"Building a computing solution for AI inference is going to be the grand prize," Sheth said.

WATCH: From GPUs to TPUs, here's how the top AI chips work

watch now

Upstart Holdings, Inc. (UPST) Presents at Morgan Stanley US Financials Conference 2026 Transcript